TY - CHAP
T1 - Evolving relevance of neuroproteomics in Alzheimer’s disease
AU - Lista, Simone
AU - Zetterberg, Henrik
AU - O’Bryant, Sid E.
AU - Blennow, Kaj
AU - Hampel, Harald
N1 - Funding Information:
H.H. and S.L. are supported by the AXA Research Fund, the Fondation Université Pierre et Marie Curie and the “Fondation pour la Recherche sur Alzheimer,” Paris, France. The research leading to these results has received funding from the program “Investissements d’avenir” ANR-10-IAIHU-06. H.Z. and K.B. are supported by the Swedish Research Council and Alzheimer’s Association and cochair the Alzheimer’s Association Global Biomarker Standardization Consortium.
Publisher Copyright:
© Springer Science+Business Media LLC 2017.
PY - 2017
Y1 - 2017
N2 - Substantial progress in the understanding of the biology of Alzheimer’s disease (AD) has been achieved over the past decades. The early detection and diagnosis of AD and other age-related neurodegenerative diseases, however, remain a challenging scientific frontier. Therefore, the comprehensive discovery (relating to all individual, converging or diverging biochemical disease mechanisms), development, validation, and qualification of standardized biological markers with diagnostic and prognostic functions with a precise performance profile regarding specificity, sensitivity, and positive and negative predictive value are warranted. Methodological innovations in the area of exploratory high-throughput technologies, such as sequencing, microarrays, and mass spectrometry-based analyses of proteins/peptides, have led to the generation of large global molecular datasets from a multiplicity of biological systems, such as biological fluids, cells, tissues, and organs. Such methodological progress has shifted the attention to the execution of hypothesisindependent comprehensive exploratory analyses (opposed to the classical hypothesis-driven candidate approach), with the aim of fully understanding the biological systems in physiology and disease as a whole. The systems biology paradigm integrates experimental biology with accurate and rigorous computational modelling to describe and foresee the dynamic features of biological systems. The use of dynamically evolving technological platforms, including mass spectrometry, in the area of proteomics has enabled to rush the process of biomarker discovery and validation for refining significantly the diagnosis of AD. Currently, proteomics—which is part of the systems biology paradigm—is designated as one of the dominant matured sciences needed for the effective exploratory discovery of prospective biomarker candidates expected to play an effective role in aiding the early detection, diagnosis, prognosis, and therapy development in AD.
AB - Substantial progress in the understanding of the biology of Alzheimer’s disease (AD) has been achieved over the past decades. The early detection and diagnosis of AD and other age-related neurodegenerative diseases, however, remain a challenging scientific frontier. Therefore, the comprehensive discovery (relating to all individual, converging or diverging biochemical disease mechanisms), development, validation, and qualification of standardized biological markers with diagnostic and prognostic functions with a precise performance profile regarding specificity, sensitivity, and positive and negative predictive value are warranted. Methodological innovations in the area of exploratory high-throughput technologies, such as sequencing, microarrays, and mass spectrometry-based analyses of proteins/peptides, have led to the generation of large global molecular datasets from a multiplicity of biological systems, such as biological fluids, cells, tissues, and organs. Such methodological progress has shifted the attention to the execution of hypothesisindependent comprehensive exploratory analyses (opposed to the classical hypothesis-driven candidate approach), with the aim of fully understanding the biological systems in physiology and disease as a whole. The systems biology paradigm integrates experimental biology with accurate and rigorous computational modelling to describe and foresee the dynamic features of biological systems. The use of dynamically evolving technological platforms, including mass spectrometry, in the area of proteomics has enabled to rush the process of biomarker discovery and validation for refining significantly the diagnosis of AD. Currently, proteomics—which is part of the systems biology paradigm—is designated as one of the dominant matured sciences needed for the effective exploratory discovery of prospective biomarker candidates expected to play an effective role in aiding the early detection, diagnosis, prognosis, and therapy development in AD.
KW - Alzheimer’s disease
KW - Biomarkers
KW - Blood
KW - Cerebrospinal fluid
KW - Detection/diagnosis
KW - Mass spectrometry
KW - Neuroproteomics
KW - Omics sciences
KW - Plasma/serum
KW - Proteomics
KW - Systems biology
UR - http://www.scopus.com/inward/record.url?scp=85019599153&partnerID=8YFLogxK
U2 - 10.1007/978-1-4939-6952-4_5
DO - 10.1007/978-1-4939-6952-4_5
M3 - Chapter
C2 - 28508359
AN - SCOPUS:85019599153
T3 - Methods in Molecular Biology
SP - 101
EP - 115
BT - Methods in Molecular Biology
PB - Humana Press Inc.
ER -